
Opinion|Videos|September 3, 2024
Luspatercept in Lower Risk MDS: Insights on the COMMANDS Trial
Medical experts offer insights on the COMMANDS trial findings.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Discuss the expanded indication of luspatercept in lower-risk myelodysplastic syndromes (based on the COMMANDS trial findings) and its implications for clinical practice.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
House Republicans Block Vote on ACA Subsidy Extension
2
Zasocitinib Hits Phase 3 End Points in Plaque Psoriasis
3
FDA Approval of Subcutaneous Amivantamab Offers Faster, Safer Option for EGFR-Mutated NSCLC
4
Study Suggests Adding BTKi to Chemo May Improve Early Outcomes in Richter Transformation in CLL
5




































